Treats pain of osteoarthritis of the knee(s). ANDA 208098, held by Sun Pharma Canada. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 208098 (Diclofenac Sodium), held by Sun Pharma Canada, was first approved by FDA on Sep 29, 2022, with 1 approved supplement and 0 published complete response letters.
Diclofenac sodium topical solution is indicated for the treatment of the pain of osteoarthritis of the knee(s).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 29, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium2% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 29, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters